Ogivri 150mg (Trastuzumab)

Adult dosage

For metastatic and early-stage breast cancer and metastatic gastric cancer, there are 1-week and 3-week regimens. 1-week regimen: - Initial loading dose: 4mg/kg - Maintenance dose: 2mg/kg weekly, starting one week after the initial loading dose 3-week regimen: - Initial loading dose: 8mg/kg - Maintenance dose: 6mg/kg every 3 weeks, starting three weeks after the initial loading dose In combination with docetaxel or paclitaxel.

This drug may affect heart function, so patients with heart disease or those who have had previous heart problems must undergo a thorough cardiac evaluation before administration. Special caution is required for patients with conditions that stress the heart, such as heart failure, angina, or hypertension. Allergic reactions or infusion-related side effects may occur during administration; therefore, the patient's condition must be closely monitored during the infusion. If symptoms such as shortness of breath, hypotension, or rash occur, administration should be stopped immediately, and appropriate treatment should be initiated. There is also a risk of lung issues, so patients with lung disease or symptoms of shortness of breath should avoid this medication. It should not be administered to patients with a history of hypersensitivity or severe shortness of breath. Various side effects such as decreased blood cell counts, infections, nausea, vomiting, diarrhea, hair loss, myalgia, etc. can occur, so any unusual symptoms should be reported to healthcare personnel immediately. Women who are pregnant or may become pregnant should use effective contraception during and for a period after treatment, and it is safest to avoid using this drug while breastfeeding. The safety and efficacy for children under 18 years of age have not been established, so it should not be used in this demographic. Additionally, while this drug does not significantly affect driving or machine operation ability, caution is needed if infusion-related symptoms occur. It is important to undergo precise testing before administration, regularly check heart and lung function during administration, and respond quickly to any side effects.

Serious side effects

Urticaria, angioedema, severe swelling (edema), chest tightness, difficulty breathing, cold sweat, pallor, high fever, severe rash, blisters, skin peeling, pain in oral/ocular mucosa, severe dermatologic reactions, shortness of breath or difficulty breathing, asthma attacks, respiratory abnormalities accompanied by cough and fever, jaundice (yellowing of skin or eyes), profound lethargy, liver dysfunction (jaundice), sudden and severe headache, thunderclap headache.

Mild side effects

• Nausea
• myalgia
• neuropathy
• fever
• sensory disturbances
• chills
• loss of appetite
• peripheral neuropathy
• vomiting
• asthenia

This drug should be stored in a sealed container to prevent exposure to air or moisture. Additionally, it is important to store it at refrigerated temperatures between 2 to 8 degrees Celsius to maintain its effectiveness.

Appearance

A colorless injectable solution filled in a vial containing a white to pale yellow freeze-dried powder, which becomes a colorless to pale yellow clear or slightly cloudy liquid when diluent is added.

Package unit

1 vial/box [vial (150.0mg)]